https://pittplusme.org/study/2173
eMonarcHER Research Study
STUDY BASICS
Have you been diagnosed with HR+, HER2+ early breast cancer? Have you had surgery to remove all of the breast cancer? You may be able to take part in a study to help find out if there is a benefit to adding an investigational medication to standard endocrine therapy. Eligible participants will receive either endocrine therapy and the investigational medication or endocrine therapy and a placebo.
IRB: 20210055
- eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in Participants with High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
MEET THE RESEARCHER
Adam Brufsky
Adam M. Brufsky, MD, PhD, is Associate Chief and Professor of Medicine in the Division of Hematology/Oncology in the Department of Medicine at the University of Pittsburgh and Associate Director of Clinical Investigation for the University of Pittsburgh Cancer Institute. Dr. Brufsky received his medical degree and doctorate from the University of Connecticut School of Medicine. He completed his residency in internal medicine at Brigham and Women's Hospital, Harvard Medical School and a fellowship in medical oncology and bone marrow transplantation at the Dana-Farber Cancer Institute. Dr. Brufsky’s research interests include novel therapies for breast cancer, bone-breast cancer interactions and therapeutics, and the molecular biology of metastatic breast cancer.